Brean Murray Carret & Co. maintains a 'Buy' on Achillion Pharmaceuticals (ACHN); Removes From N-T Focus List, But Dip Offers Investor Opportunity

Brean Murray Carret & Co. maintains a 'Buy' on Achillion Pharmaceuticals (NASDAQ: ACHN) price target of $20.00.

Analyst, Brian Skorney, said, "Achillion shares were down materially last week following unprecendented data from Bristol-Myers (NYSE: BMY) and Gilead (Nasdaq: GILD) showing the potential for a nuc-based oral regimen to cure a large percentage of patients. We believe a further dip in shares would represent a compelling buying opportunity as we believe the confusion over the safety/efficacy profile of ACH-1625...has created more questions about the role ACH-1625 could play in an all oral regimen."

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $8.28 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS